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Abstract
Objective To investigate the risk of pancreatitis associated with the use
of incretin-based treatments in patients with type 2 diabetes mellitus.
Design Systematic review and meta-analysis.
Data sources Medline, Embase, the Cochrane Central Register of
Controlled Trials (CENTRAL), and ClinicalTrials.gov.
Eligibility criteria Randomised and non-randomised controlled clinical
trials, prospective or retrospective cohort studies, and case-control
studies of treatment with glucagon-like peptide-1 (GLP-1) receptor
agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors in adults with type
2 diabetes mellitus compared with placebo, lifestyle modification, or
active anti-diabetic drugs.
Data collection and analysis Pairs of trained reviewers independently
screened for eligible studies, assessed risk of bias, and extracted data.
A modified Cochrane tool for randomised controlled trials and a modified
version of the Newcastle-Ottawa scale for observational studies were
used to assess bias. We pooled data from randomised controlled trials
using Peto odds ratios, and conducted four prespecified subgroup
analyses and a post hoc subgroup analysis. Because of variation in
outcome measures and forms of data, we describe the results of
observational studies without a pooled analysis.
Results 60 studies (n=353 639), consisting of 55 randomised controlled
trials (n=33 350) and five observational studies (three retrospective
cohort studies, and two case-control studies; n=320 289) were included.
Pooled estimates of 55 randomised controlled trials (at low or moderate
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risk of bias involving 37 pancreatitis events, raw event rate 0.11%) did
not suggest an increased risk of pancreatitis with incretins versus control
(odds ratio 1.11, 95% confidence interval 0.57 to 2.17). Estimates by
type of incretin suggested similar results (1.05 (0.37 to 2.94) for GLP-1
agonists v control; 1.06 (0.46 to 2.45) for DPP-4 inhibitors v control).
Analyses according to the type of control, mode, duration of treatment,
and individual incretin agents suggested no differential effect by
subgroups, and sensitivity analyses by alternative statistical modelling
and effect measures did not show important differences in effect
estimates. Three retrospective cohort studies (moderate to high risk of
bias, involving 1466 pancreatitis events, raw event rate 0.47%) also did
not suggest an increased risk of pancreatitis associated with either
exenatide (adjusted odds ratios 0.93 (0.63 to 1.36) in one study and 0.9
(0.6 to 1.5) in another) or sitagliptin (adjusted hazard ratio 1.0, 0.7 to
1.3); a case-control study at moderate risk of bias (1003 cases, 4012
controls) also suggested no significant association (adjusted odds ratio
0.98, 0.69 to 1.38). Another case-control study (1269 cases, 1269
controls) at moderate risk of bias, however, suggested that the use of
either exenatide or sitagliptin was associated with significantly increased
odds of acute pancreatitis (use within two years v no use, adjusted odds
ratio 2.07, 1.36 to 3.13).
Conclusions The available evidence suggests that the incidence of
pancreatitis among patients using incretins is low and that the drugs do
not increase the risk of pancreatitis. Current evidence, however, is not
definitive, and more carefully designed and conducted observational
studies are warranted to definitively establish the extent, if any, of
increased risk.
Introduction
Acute pancreatitis is a serious condition that often leads to
hospital admission and even death. Important risk factors for
acute pancreatitis include gallstones, alcohol use, older age,
black race, smoking, obesity, and type 2 diabetes.1 Exposure to
certain drugs is also associated with acute pancreatitis.1
Glucagon-like peptide-1 (GLP-1) receptor agonists and
dipeptidyl peptidase-4 (DPP-4) inhibitors are two classes of
incretin based treatments for type 2 diabetes mellitus. Evidence
from randomised controlled trials has shown that GLP-1 agonists
effectively lower glycated haemoglobin (HbA1c) by about 1%,2
reduce body weight, and rarely cause hypoglycaemia when used
as monotherapy3 4; DDP-4 inhibitors have intermediate efficacy
regarding glucose control5 with no impact on body weight and
a low risk of hypoglycaemia.3 6 The American Diabetes
Association (ADA) and the European Association for the Study
of Diabetes (EASD) recommends the consideration of DPP-4
inhibitors and GLP agonists as second line treatment options.6 7
In 2008, the US Food and Drug Administration (FDA) warned
of a strong temporal association between exenatide and
pancreatitis on the basis of 30 case reports of acute pancreatitis.8
In 2009, the FDA notified healthcare professionals and patients
of revisions to the prescribing information for Januvia
(sitagliptin) and Janumet (sitagliptin/metformin) after
announcing the observation of 88 post-marketing cases of acute
pancreatitis.9 In 2012, one consumer group in the United States
called for the withdrawal of liraglutide10 and cautioned that
liraglutide is associated with higher than expected rates of
pancreatitis, thyroid cancer, and kidney failure based on the
following statement from FDA reviewers: “in clinical trials
patients taking liraglutide had a risk of pancreatitis that was 3.7
fold higher than the risk in patients taking other antidiabetes
drugs.” In 2013, the concerns regarding the risk of pancreatitis
and pancreatic cancer continued to grow, resulting in
international debate.11 12 The BMJ has published several
commentaries discussing the potential risk of pancreatitis and
implications of using incretin based drugs.13-17 The FDA also
has announced ongoing efforts to assess the risk of pancreatic
associated with incretins.18Yet the definitive recommendations
regarding the risk are not available.
Findings from animal studies have been inconsistent. Some
showed that exenatide seemed to increase inflammation of
pancreatic acinar cells19 and formation of pancreatic
intraepithelial neoplasia20; sitagliptin increased pancreatic ductal
turnover and ductal metaplasia.21Others suggested that exenatide
improved chemically induced pancreatitis in normal and diabetic
rodents22 and that liraglutide induced cytokines with
anti-inflammatory effects.23Another study found that liraglutide
did not induce pancreatitis in mice, rats, or monkeys when it
was given for up to two years and at exposure concentrations
up to 60 times higher than in used in humans.24
Results from drug safety surveillance systems have been more
concerning. The evidence to support a causal relation between
incretin based drugs and pancreatitis is weak. Most safety data
have been acquired through the FDA adverse event reporting
system (AERS),8 9 25 by which an appropriate selection of control
and collection of information regarding the exposure and
confounding factors is challenging. Because of ongoing safety
concerns, there is a clear need for a rigorous evaluation of the
safety of GLP-1 agonists and DPP-4 inhibitors. We conducted
a systematic review of randomised and non-randomised studies
to provide a comprehensive assessment regarding the risk of
pancreatitis associated with GLP-1 agonists and DPP-4
inhibitors relative to placebo or active drugs.
Methods
Eligibility criteria
We included randomised and non-randomised controlled trials,
prospective and retrospective cohort studies, and case-control
studies that enrolled adult patients with type 2 diabetes mellitus;
included an unconfounded comparison of GLP-1 agonists or
DPP-4 inhibitors against placebo, lifestyle modification, or
active antidiabetic drugs; followed up patients for at least 12
weeks (not applicable for case-control studies); and explicitly
reported event data on pancreatitis.
To be classified as an unconfounded comparison, we required
that planned interventions were identical between treatment and
control groups except the GLP-1 agonists or DDP-4 inhibitors
under consideration. We also required that authors clearly and
explicitly reported numbers of pancreatitis events in all treatment
groups under consideration.
Literature search
We searched Medline, Embase, and the Cochrane Central
Register of Controlled Trials (CENTRAL) up to March 2013
for published studies without language restrictions. We used
both MeSH and free text terms to identify relevant articles. An
information expert (DP) developed the search strategy (appendix
1). At the time of searching, we planned to investigate the effect
of incretin treatments on people with and without on diabetes.
We thus included search terms defining incretin drugs and study
designs only.
We also searched ClinicalTrials.gov to identify additional
eligible clinical trials. This trial registry documents all drug
trials other than phase I studies as required by Section 801 of
the US Food and Drug Administration Amendments Act
(FDAAA 801)26 and typically includes extensive lists of adverse
events.27 This provides important information regarding data on
pancreatitis.We searched generic names of each individual drug
to ensure high sensitivity. We undertook the search of
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ClinicalTrials.gov in August 2013 to ensure that data from
previously published trials were updated on the registry. We
limited our search to those trials labelled as “completed” and
for which results were available.
Study process
We developed standardised pilot-tested forms together with
detailed instructions for screening of abstracts and full text, risk
of bias assessment, and data collection. Pairs of reviewers with
training in research methods, independently and in duplicate,
screened study reports for eligibility, assessed risk of bias, and
collected data from each eligible study. Reviewers dealt with
discrepancies through discussion or, if required, adjudication
by a third reviewer (XS).
Risk of bias assessment
We used a modified version of Cochrane Collaboration’s tool28
to assess the risk of bias of randomised controlled trials. We
considered random sequence generation; allocation concealment;
blinding of participants, caregivers, and outcome (that is,
pancreatitis) assessors; adjudication of pancreatitis events;
prognostic balance between treatment groups; and selective
outcome reporting. In assessing the risk of bias with blinding,
our modified instrument removed the “unclear” option for the
assessment of blinding, an approach we have previously
validated.29
We used a modified version of the Newcastle-Ottawa quality
assessment scale30 to assess the risk of bias in cohort and
case-control studies. For cohort studies, we removed the item
regarding representativeness of sample and the item “was the
follow-up long enough?” as these items relate to applicability
of results. For case-control studies, we also removed the item
“representativeness of the cases.” For both types of studies, we
added two items, one dealing with ascertainment of type 2
diabetes and another with ascertaining confounding variables.
We did not assess publication bias because of the low power
associated with studies of rare events.
Data collection
From eligible randomised controlled trials we collected
information on study characteristics (study design, sample size,
number of treatment groups, length and design (such as variable
or fixed) of follow-up, funding source, registry number, whether
trials were international and, if so, countries involved, number
of study sites, and study phase); patient characteristics (sex,
age, duration of type 2 diabetes, baseline HbA1c concentrations,
body mass index (BMI), and fasting plasma glucose);
interventions (drugs commonly used across all groups (baseline
treatment), incretin treatment, control group, dose, intensity,
and duration of treatment); pancreatitis events in each of the
treatment groups; and number of patients included for analyses
in each of the treatment groups (that is, considered as a safety
set).
For extension randomised controlled trials, in which treatment
assignments were switched (for example, patients in placebo
group started receiving incretins), we documented only the
outcome data before that point. For multiple reports of the same
trial, we collated all data into a single study.31 If outcome data
for pancreatitis were reported at multiple follow-up points, we
used data from the longest follow-up.
For observational studies, we documented information as for
randomised controlled trials, when applicable. Additionally, we
collected information regarding study design (such as
retrospective cohort study), sources of data (such as claims
data), method of ascertaining type 2 diabetes status (such as
ICD (international classification of diseases) code), exposures
(such as incretins, and such exposure variables as age), method
of adjustment for confounding (such as adjustment or matching,
and variables used for these techniques), and follow-up. We
also documented unadjusted and adjusted results, in addition to
raw event data and exposure time.
Data analysis
We analysed randomised controlled trials and observational
studies separately. For randomised trials, we assessed
heterogeneity between studies using a χ2 test and the I2 statistic.
We pooled trials using Peto’s methods32 33 and reported pooled
Peto odds ratios and their associated 95% confidence intervals.
P<0.05 was considered significant. We explored sources of
heterogeneity with four a priori subgroup hypotheses: type of
incretin (GLP-1 agonists v control; DPP-4 inhibitors v control);
type of control (incretin v placebo, incretin v active treatment);
length of follow-up (incretin v control by subgroup of ≤26
weeks, 26-52 weeks, >52 weeks); and mode of treatment
(incretin monotherapy v control, incretin add-on/combination
treatment v control), and a post hoc subgroup analysis of
different incretins. We undertook sensitivity analyses by using
alternative effect measures (odds ratio v relative risk), pooling
methods (Peto methods vMantel-Haenszel method), and
consideration on heterogeneity (random v fixed effect).
We qualitatively analysed the data from observational studies
because of differences in outcomemeasures, exposures (that is,
drug under consideration), and forms of outcome data (that is,
adjusted v unadjusted data; hazard ratio v incidence rate ratio).
We reported the results according to meta-analysis of
observational studies in epidemiology (MOOSE)34 and preferred
reporting items for systematic reviews and meta-analyses
(PRISMA).35
Results
Our search yielded 7432 potentially relevant reports. After
screening titles and abstracts, we retrieved 468 reports for full
text screening. Fifty nine studies, including 55 randomised
controlled trials36-90 (40 from journals and 15 from the trial
registry) reported in 61 reports, three cohort studies,91-93 and one
case-control study94 were eligible for inclusion (fig 1⇓). Eight
months after our formal search (November 2013), however, an
additional large case-control study95was published.We therefore
also included this study, resulting in inclusion of two
case-control studies. These studies recruited 353 639 patients,
including 33 350 from randomised controlled trials and 320 289
from observational studies. Three other retrospective cohort
studies also examined risk of pancreatitis with incretin drugs96-98;
they did not explicitly limit patients to those with type 2 diabetes
mellitus and were therefore excluded (appendix 2).
Evidence from randomised controlled trials
The 55 randomised controlled trials—all industry funded—were
conducted in 2-49 (median 11) countries and 3-268 (median
110) study sites; 45 (82%) were international and 44 (80%)
were phase III studies. The length of follow-up ranged from 12
to 234 weeks. The trials enrolled 69 to 1615 patients (total 33
350), with a mean age range of 49.7-66.5, mean BMI range of
24.5-36.7, mean baseline HbA1c range of 7.3-9.8%, mean
fasting plasma glucose range of 7.7-11.3 mmol/L, and mean
duration of diabetes range of 1-16.7 years (table 1⇓). None of
the studies explicitly mentioned their criteria for diagnosis of
pancreatitis.
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Twenty seven randomised controlled trials testedGLP-1 receptor
agonists, 26 tested DDP-4 inhibitors, and two tested both agents;
17 tested incretin monotherapy, and 38 used incretin agents as
add-on or combination treatment (table 2⇓). Duration of
treatment ranged from 12-107weeks (median 26; 22 trials longer
than 26 weeks).
Thirty six randomised controlled trials (66%) adequately
generated random sequence, 33 (60%) adequately concealed
allocation (appendix 3); 47 (86%) blinded patients, caregivers,
and outcome assessors. None of the trials adjudicated
pancreatitis events.
Risk of pancreatitis in randomised trials
Of the 55 randomised controlled trials reporting pancreatitis,
27 explicitly stated that no events of pancreatitis occurred during
the course of study. Eight studiesmentioned pancreatic enzymes;
none, however, reported usable data. Overall, 37 pancreatitis
events occurred in 33 227 patients who used at least one drug
(raw event rate 0.11%). Results did not show a significant
difference between incretins versus control (odds ratio 1.11,
95% confidence interval 0.57 to 2.17; fig 2⇓).
When we explored the sources of heterogeneity, the risk did not
differ by the type of incretin (GLP-1 agonists vDPP-4 inhibitors;
interaction test P=0.99): 29 trials, involving 14 562 patients and
16 pancreatitis events (0.11%) compared GLP-1 agonists versus
control (odds ratio 1.05, 95% confidence interval 0.37 to 2.94);
28 trials, involving 19 241 patients and 23 events (0.12%)
compared DPP-4 inhibitors versus control (1.06, 0.46 to 2.45).
Neither analysis suggested an increased risk of pancreatitis (fig
A in appendix 4).
The subgroup analysis by type of control (that is, placebo v
active drug) did not suggest apparent difference (odds ratio 1.27
in trials comparing with placebo, 1.00 in those comparing with
active drug treatments; interaction P=0.72) (fig B in appendix
4). Exploration of the effect by the mode of treatment
(monotherapy v add-on/combination treatment) also did not
suggest significant difference (0.84 monotherapy v 1.22
add-on/combination treatment; interaction P=0.63) (fig C in
appendix 4). Nor was there a difference by length of follow-up
(interaction P=0.84; odds ratio 0.90 at 26 weeks or shorter v
1.44 at 26-52 weeks v 1.14 over 52 weeks) (fig D in appendix
4). The post hoc analysis of individual incretins did not show
difference among those agents (fig E in appendix 4).
The sensitivity analysis using alternative effect measures
(relative risk v odds ratio), statistical models (Mantel-Haenszel
v Peto) and considerations on heterogeneity (random effect v
fixed effect) did not show important change in the pooled effects
(figs F-H in appendix 4).
Evidence from observational studies
Of the five observational studies, three retrospective cohort
studies examined the risk of acute pancreatitis associated with
the use of exenatide, sitagliptin, or both,91-93 and two case-control
studies specifically assessed the risk of admission to hospital
for acute pancreatitis in patients with type 2 diabetes taking
incretins 94 95 (tables 3⇓ and 4⇓).
Of the three cohort studies, the first included 38 615 patients
with diabetes (6545 exenatide, 15 826 sitagliptin, and 16 244
control) recruited in the US Medco National Integrated
Database.91 Patients aged 18-63 were identified with ICD-9 code
for drugs for type 2 diabetes and were followed up for a mean
of 0.7 year (0.6 exenatide, 0.8 sitagliptin, 0.7 control). Exposure
to incretins was probably identified from pharmacy claims.
Study investigators computed a chronic disease score based on
pharmacy claims data and identified risk factors for pancreatitis,
including drugs and medical conditions by using pharmacy
claims and ICD-9 codes. Acute pancreatitis was identified with
ICD-9 codes; 154 pancreatitis events (0.4%) occurred (22 in
the exenatide group (0.3%), 67 in the sitagliptin group (0.4%),
65 in the control group (0.4%)), with a corresponding incidence
of 563.9 cases per 100 000 patient years (569.9 in the exenatide
group, 554.4 in the sitagliptin group, and 571.9 in the control
group). After adjustment for the influence of age, sex, history
of pancreatic disease, alcohol intake, biliary stone disease,
hypertriglyceridaemia, and chronic disease score, the risk of
acute pancreatitis was similar between exenatide and control
(adjusted hazard ratio 0.9, 95% confidence interval 0.6 to 1.5)
and sitagliptin and control (1.0, 0.7 to 1.3).
The second study included 268 561 patients (530 574 patient
years, 13 791 patient years in exenatide group, 516 783
non-exenatide) with type 2 diabetes from an employer-provided
health insurance covering about 6.6 million employees in the
US.92 Patients were aged 63.1 on average, with mean duration
of diabetes of 3.1 years. Study investigators used ICD-9 codes
to identify patients with type 2 diabetes and their pancreatic
outcome (admission for acute pancreatitis, code 577.0). The
information regarding exposure to exenatide was identified by
National Drug Codes. They also used ICD-9 codes to identify
information regarding a set of 19 co-morbid conditions (such
as congestive heart failure, chronic obstructive pulmonary
disease, and stroke) and traditional risk factors for pancreatitis.
They identified 1312 (0.5%) admissions for acute pancreatitis
events (27 in those taking exenatide, 1285 in those not taking
exenatide), with corresponding incidence of 247.3 cases per
100 000 patient years (195.8 for exenatide, 248.7 for
non-exenatide). The risk of admission for acute pancreatitis in
patients who have used exenatide was not statistically different
(0.20% v 0.25%; adjusted odds ratio 0.93, 95% confidence
interval 0.63 to 1.36) after adjustment for age, sex, years since
diagnosis of diabetes, year of observation, 19 co-morbid
conditions, and traditional risk factors for pancreatitis.
The third study recruited 5560 patients from a diabetes specialty
care centre in India.93Of these patients, 2817 received sitagliptin
and 2743 self injected insulin glargine. Information regarding
ascertainment of other variables (confounders), however, was
not reported. This study found no patient with either symptoms
or signs of acute pancreatitis in the sitagliptin or insulin glargine
group.
The first case-control study identified 1269 cases (admissions
for acute pancreatitis) and 1269 controls from administrative
claims of Blue Cross Blue Shield plan.94 All of these patients,
aged 52 on average, had type 2 diabetes, as confirmed by ICD-9
codes or drug history for hyperglycaemia. Patients with type 1
diabetes or gestational diabetes were excluded. Cases were
identified with a validated algorithm based on ICD-9 and current
procedural terminology codes for acute pancreatitis, and
occurrences of pancreatitis within three months of enrolment
were excluded. Controls were selected, on a 1:1 ratio, for each
case; they were matched for age within 10 years, sex, insurance
plan site, diabetes complication severity index, and enrolment
pattern or duration of follow-up. Information on drug exposure
(exenatide or sitagliptin) was identified from the pharmacy
database. No information was available regarding the
ascertainment of risk factors for acute pancreatitis and use of
other drugs. After we controlled for the influence of
hypertriglyceridaemia, alcohol use, gallstones, tobacco abuse,
obesity, biliary and pancreatic cancer, cystic fibrosis, an
indicator of general morbidity level, and metformin exposure
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during the same period, we found that use of sitagliptin or
exenatide within 30 days before pancreatitis versus non-use
(that is, no use for more than two years before the index date
of pancreatitis event; adjusted odds ratio 2.24, 95% confidence
interval 1.36 to 3.68), recent use (30 days to two years before
admission; 2.01, 1.37 to 3.18), and any use within two years
(2.07, 1.36 to 3.13) were associated with significantly increased
odds of acute pancreatitis.
The second case-control study, conducted in Italy, assessed the
use of incretins (exenatide, liraglutide, sitagliptin, saxagliptin,
and vildagliptin).95 This study identified 1003 cases (admission
for acute pancreatitis) and 4012 controls matched for year of
birth, sex, and year of first exposure to antidiabetic drugs from
regional administrative data of the Italian national health system
that allowed the linkage of drugs dispensed with hospital
discharges. All the patients with type 2 diabetes, dispensed at
least one dose of antidiabetic drugs and aged 72 on average,
were identified according to the ICD-9 system. Patients coded
for type 1 diabetes (250.x1, 250.x3) were excluded. Cases were
identified through the ICD-9 code (577.0) at discharge. The
exposure to incretins and other antidiabetic drugs (metformin
or glibenclamide) was measured according to the anatomical
therapeutic classification system. Potential confounders—history
of chronic or acute pancreatitis, gallstones, alcohol misuses,
biliary tract or pancreatic cancers, and admission for
cardiovascular diseases and diabetic retinopathy—were
measured with ICD-9 codes. After adjustment for those
confounders and the use of other antidiabetic drugs, the adjusted
analyses did not show a significant association between the
exposure to incretins and the risk of admission for acute
pancreatitis (adjusted odds ratio 0.98, 95% confidence interval
0.69 to 1.38).
Risk of bias in observational studies
All observational studies used either claims data or patients’
medical records for their analyses. Studies using claims data or
medical records confirmed diagnosis of type 2 diabetes, drug
exposures, confounding factors, and occurrence of pancreatitis
based on ICD-9 codes and pharmacy claims data (tables 5 and
6⇓⇓). The approaches for ascertaining type 2 diabetes differed
across those studies (the ICD-9 codes they used varied), and
the accuracy of ascertaining type 2 diabetes remains unclear.
Three studies described themethod for ascertaining confounding
factors and the use of drugs other than incretins.91 92 95 Though
the four studies that used claims data adjusted for the
association, they chose different variables, leaving the adequacy
of adjustment questionable. All studies failed to report the extent
to which the claims data were complete in the overall database.
Because of these limitations the risk of bias associated with
eligible observational data was moderate to high.
Discussion
Main findings
In this systematic review and analysis of 55 randomised trials
(low to moderate risk of bias involving 37 cases of pancreatitis
among 33 227 patients), three retrospective cohort studies
(moderate to high risk of bias involving 1466 pancreatitis events
among 312 736 patients), and one case-control study (moderate
risk of bias involving 1003 patients admitted to hospital for
acute pancreatitis) we found no evidence to suggest an increased
risk of pancreatitis associated with the use of incretins in patients
with type 2 diabetes. The other case-control study (1269 patients
admitted for acute pancreatitis), at moderate risk of bias,
reported increased risk of admission for pancreatitis associated
with the use of sitagliptin or exenatide.
The incidence of pancreatitis was low. In randomised trials,
pancreatitis occurred in 0.11% of patients (0.11% in those taking
incretins; 0.11% in control patients). In cohort studies, the risk
of acute pancreatitis and admission for pancreatitis was higher
(0.47%) than the risk in randomised trials, potentially because
of a higher incidence of risk factors such as gallstones and longer
follow-up.
Our findings should be interpreted cautiously. Although we
included a large number of randomised trials, those trials were
typically designed for testing efficacy. Many had relatively
small sample sizes and relatively short follow-up. Because
pancreatitis is rare and the event rates low, the confidence
intervals around relative effects are wide, leaving the possibility
of an undetected increase in risk. Furthermore, these
trials—mostly phase III studies—often recruited patients with
less co-morbidity than patients seen in clinical practice. The
risk in the non-exposed patient group is therefore lower than
usual (as above 0.11% in trials v 0.47% in observational studies).
This in part explains the wide confidence intervals and also
limits generalisability of the results.
There are further potential limitations of the randomised trials.
Trials could have failed to document pancreatitis events or, if
documented, failed to report these events (that is, selective
reporting bias). Pancreatitis, however, is usually considered a
serious adverse event in trials of type 2 diabetes, and, according
to FDA’s policy, the reporting of serious adverse event data is
mandatory to ClinicalTrials.gov,27 limiting the risk of lack of
monitoring and selective reporting. Even if pancreatitis events
were monitored, however, they might not have been
independently adjudicated, raising the possibility of inaccurate
data.
A final issue is the possibility of failure to identify patients with
subclinical minimally symptomatic pancreatitis. The increase
of pancreatic enzyme activity (lipase and amylase), a surrogate
measure, could represent supporting evidence in the assessment
of the risk of pancreatitis; these data, however, were not readily
usable.
The five observational studies, involving patients in real practice,
had large sample sizes, but had limitations related to use of
claims data or patients’ medical records. Because most studies
relied on the ICD-9 coding system to identify study populations
and outcomes, the ascertainment of type 2 diabetes, and
particularly pancreatitis, was probably inadequate because of
the variation of diagnosis criteria and lack of outcome
adjudication. Similar to the situation with trials, subclinical and
minimally symptomatic cases of pancreatitis were less likely
to be identified in those studies. Additionally, the exposure to
incretins and control drugs and the exposure to other
confounding factorsmight not have been accurately documented.
The completeness of data within each of those databases is also
unclear; investigators might have excluded those without
complete exposure and outcome data from analyses. Finally,
the accurate measurement and adjustment for other prognostic
factors was limited. Overall, the risk of bias was moderate to
high in all observational studies.
Among those five observational studies, a single case-control
study suggested an increased risk of admissions for acute
pancreatitis; the four others, including three cohort studies and
one case-control study, did not. Of the four studies suggesting
no increased risk, three consistently reported the point estimates
close to 1 and the confidence intervals were similar (0.6 to 1.5).
The reasons for discrepancy between the single case-control
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study and the other studies are not clear: the selection of
different study populations (that is, different age groups, thus
differing baseline risk) and different choices of exposures and
non-exposures are possible explanations. Varying risk of bias
and inadequate control of confounders are other explanations.
In addition to those five eligible observational studies, three
retrospective cohort studies (appendix 2), at moderate risk of
bias and that failed to limit patients to those with type 2 diabetes
(and were therefore excluded), reported the risk of acute
pancreatitis associated with exenatide.96-98 These studies
consistently suggested that exenatide was not associated with
an increased risk of acute pancreatitis.
The FDA adverse drug event system has documented 2327
spontaneously reported cases of pancreatitis in patients taking
exenatide, 888 case in those taking liraglutide, 718 cases in
those taking sitagliptin, and 125 cases in those taking
saxagliptin.12 The number of cases of pancreatitis seemed larger
in those taking incretins than other active antidiabetic drugs,
suggesting a potentially increased risk. The absence of data on
number of patients exposed to those antidiabetic drugs, and the
possibility of a lower threshold of reporting with new drugs,
however, severely limits the usefulness of these data for making
causal inferences.
Strengths and limitations
Our study has several strengths. Firstly, we systematically
identified and included both randomised and non-randomised
studies to examine the risk of pancreatitis associated with
incretin treatment. Secondly, in addition to published reports,
we searched ClinicalTrials.gov, which provided additional
outcome information and eligible trials. Thirdly, we instituted
a rigorous approach to ensure the data were accurate, in
particular using the data on pancreatitis reported in
ClincialTrials.gov and journal publications for consistency.
We did not assess the risk of pancreatic cancer associated with
the use of incretins. Although studies have suggested a
potentially increased risk, they have many limitations.99 The
FDA adverse drug event system documented 258 cases of
pancreatic cancer in patients taking exenatide, 63 cases in those
taking liraglutide, 81 cases in those taking sitagliptin, and 18
cases in those taking saxagliptin.12 The number of cancer cases
did not seem larger in patients taking incretins (except exenatide)
than other drugs for diabetes. We also did not specifically assess
the risk of chronic pancreatitis associated with the use of
incretins; few data on this issue are available.
Comparison with other studies
Two other meta-analyses have assessed the risk of pancreatitis
among patients using incretins, one examining GLP-1 agonists100
and another DPP-4 inhibitors.101 The first meta-analysis,
involving 22 randomised controlled trials and three retrospective
cohort studies, reported no significant association between
pancreatitis events and the exposure to exenatide or liraglutide.100
This analysis pooled results of randomised trials and large
observational studies, making the interpretation of estimates
challenging: in 10 randomised controlled trials and three
retrospective cohort studies the odds ratio for exenatide was
0.84 (95% confidence interval 0.58 to1.22) and in the combined
results of 10 randomised controlled trials the odds ratio for
liraglutide was 0.97 (0.21 to 4.39). Furthermore, this study
included two cohort studies, in which patients might not be
strictly limited to those with type 2 diabetes mellitus and were
thus excluded from our review. The second study was a
meta-analysis of exclusively randomised controlled trials,
investigated risk of pancreatitis in DDP-4 inhibitors.101 It found
that DPP-4 inhibitors were not associated with an increased risk
of pancreatitis (odds ratio 0.93, 95% confidence interval 0.51
to 1.69).101Bothmeta-analyses included trials that had no explicit
information regarding pancreatitis; they might have assumed
that no pancreatitis occurred in such trials. It is probably
reasonable to assume no event in the absence of reporting in
such situation. This approach, however, could artificially reduce
the incidence of pancreatitis as more patients are added to the
population whereas no events are added. In either of the
approaches (ours and those of the two other published
meta-analyses), however, the statistical model did not include
zero event trials in meta-analyses, as they are statistically
omitted in pooling relative effects. Compared with these two
meta-analyses, our study included five observational studies
that carry more important information regarding the risk of
pancreatitis.
Conclusion
In summary, the available evidence suggests that the incidence
of pancreatitis in patients taking incretins is low and that these
drugs do not increase the risk of pancreatitis. The current body
evidence, however, is not definitive, andmore carefully designed
and conducted observational studies are warranted to definitively
establish the extent, if any, of increased risk. In addition,
incretins, which are expensive, are no superior to widely used
antidiabetic drugs (such as metformin) for glucose control.
Given the uncertainty about the effect of incretins on important
outcomes, including pancreatitis, the lack of apparent benefits
in glucose control over other drugs, and the relatively high costs,
the use of incretins might not be preferable to other available
antidiabetic drugs.
Future demonstration of consistency of the putative association
across studies is warranted. Trialists exploring the effect of
incretins should report all adverse events affecting the pancreas.
Presentation of associations both in class of agents (such as
GLP-1 agonists) and individual incretins is important and
informative to assess the potential risk. Reporting of results for
the gradient of pancreatic outcomes—pancreatic enzymes,
asymptomatic pancreatitis, symptomatic pancreatitis, and
admission for acute pancreatitis—will also be helpful for
informing risks associated with incretin treatment. Future
randomised trials that specifically examine this issue, however,
are unlikely. We need more carefully designed and conducted
observational studies that clearly define study population,
accurately collect information regarding length to follow
exposure and confounding factors, completely collect outcome
data, and adequately adjust for the influence of confounders.
Currently, a European study is applying surveillance and
observational study methods to assess vascular and pancreatic
safety of diabetes drugs, including thiazolidinedones (TZDs),
incretins, and amylin analogues in people with type 2 diabetes.102
The resulting findings might provide more definitive evidence.
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What is already known on this topic
A number of cases of acute pancreatitis have been reported in patients with type 2 diabetes who were taking incretins
Concerns have arisen regarding the risk of pancreatitis associated with these agents, though findings from various studies are conflicting
What this study adds
Data from randomised controlled trials are not adequate to assess the risk of pancreatitis, but several large observational studies, with
methodological limitations, provide relatively precise estimates
The available evidence suggests that the incidence of pancreatitis in patients with type 2 diabetes taking incretins is low and that incretins
do not increase risk of pancreatitis
Funding: This study was funded by Young Investigator Award, Sichuan
University (project No 2013SCU04A37). JWB is funded by a New
Investigator Award from the Canadian Institutes of Health Research
and Canadian Chiropractic Research Foundation. SE is funded by
MITACS Elevate and Restracomp Postdoctoral Awards. The funders
had no role in the study design, writing of the manuscript, or decision
to submit this or future manuscripts for publication.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare:
no support from any organisation for the submitted work; no financial
relationships with any organisations that might have an interest in the
submitted work in the previous three years, no other relationships or
activities that could appear to have influenced the submitted work.
Ethical approval: Not required.
Transparency: The lead author (the manuscript’s guarantor) affirms that
the manuscript is an honest, accurate, and transparent account of the
study being reported; that no important aspects of the study have been
omitted; and that any discrepancies from the study as planned have
been explained.
Data sharing: No additional data available.
1 Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer.
Gastroenterology 2013;144:1252-61.
2 Aroda VR, Henry RR, Han J, Huang W, DeYoung MB, Darsow T, et al. Efficacy of GLP-1
receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther
2012;34:1247-58.e22.
3 Ismail-Beigi F. Glycemic management of type 2 diabetes mellitus. N Engl J Med
2012;366:1319-27.
4 Vilsboll T, ChristensenM, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1
receptor agonists on weight loss: systematic review and meta-analyses of randomised
controlled trials. BMJ 2012;344:d7771.
5 Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4
inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review
and meta-analysis. BMJ 2012;344:e1369.
6 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al.
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position
statement of the American Diabetes Association (ADA) and the European Association
for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79.
7 American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes
Care 2014;37:S14-80.
8 US Food and Drug Administration. Exenatide (marketed as BYETTA): acute pancreatitis.
www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm119034.htm#exenatide.
9 US Food and Drug Administration. Sitagliptin (marketed as Januvia and Janumet)—acute
pancreatitis. www.fda.gov/Safety/MedWatch/SafetyInformation/
SafetyAlertsforHumanMedicalProducts/ucm183800.htm.
10 Lenzer J. Consumer group calls for antidiabetes drug to be withdrawn. BMJ
2012;344:e3259.
11 Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits
by far outweigh the potential risks. Diabetes Care 2013;36:2126-32.
12 Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of
incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-25.
13 Gale E. Incretin therapy: should adverse consequences have been anticipated? BMJ
2013;346:f3617.
14 Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been
underplayed? BMJ 2013;346:f3680.
15 Kmietowicz Z. Potential harms of type 2 diabetes drugs have been ignored, finds BMJ
investigation. BMJ 2013;346:f3782.
16 Cohen D. Pressure mounts for companies to hand over data on antidiabetes drugs linked
to pancreatic harm. BMJ 2013;346:f3900.
17 Cohen D. European drugs agency clashes with scientists over safety of GLP-1 drugs.
BMJ 2013;347:f4838.
18 US Food and Drug Administration. Incretin mimetic drugs for type 2 diabetes: early
communication—reports of possible increased risk of pancreatitis and pre-cancerous
findings of the pancreas. www.fda.gov/Safety/MedWatch/SafetyInformation/
SafetyAlertsforHumanMedicalProducts/ucm343805.htm.
19 Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, et al.
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas.
Diabetologia 2010;53:153-9.
20 Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1
receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and
accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D)
mouse model. Diabetes 2012;61:1250-62.
21 Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, et al. Beneficial
endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide
transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes
2009;58:1604-15.
22 Tatarkiewicz K, Smith PA, Sablan EJ, Polizzi CJ, Aumann DE, Villescaz C, et al. Exenatide
does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and
diabetic rodents. Am J Physiol Endocrinol Metab 2010;299:E1076-86.
23 Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor
activation modulates pancreatitis-associated gene expression but does not modify the
susceptibility to experimental pancreatitis in mice. Diabetes 2009;58:2148-61.
24 Nyborg NC, Molck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide
and the pancreas: evidence for the absence of structural pancreatic changes in three
species. Diabetes 2012;61:1243-9.
25 Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and
thyroid cancer with glucagon-like peptide-1 based therapies. Gastroenterology
2011;141:150-6.
26 ClinicalTrials.gov. Why should I register and submit results? www.clinicaltrials.gov/ct2/
manage-recs/background.
27 US Food and Drug Administration. Food and Drug Administration Amendments Act
(FDAAA) of 2007. US Public Law 110-85 section 801. www.gpo.gov/fdsys/pkg/PLAW-
110publ85/pdf/PLAW-110publ85.pdf.
28 Higgins JPT AD, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT,
Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0.
Cochrane Collaboration, 2011.
29 Akl EA, Sun X, Busse JW, Johnston BC, Briel M, Mulla S, et al. Specific instructions for
estimating unclearly reported blinding status in randomized trials were reliable and valid.
J Clin Epidemiol 2012;65:262-7.
30 Wells GA SB, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa
Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. www.
ohri.ca/programs/clinical_epidemiology/oxford.asp.
31 Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions.
Version 5.1.0. Cochrane Collaboration, 2011.
32 Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a
comparison of the performance of meta-analytical methods with rare events. Stat Med
2007;26:53-77.
33 Higgins JPT Deeks JJ, Altman DG. Special topics in statistics. In: Higgins JPT, Green S,
eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Cochrane
Collaboration, 2011.
34 Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis
of observational studies in epidemiology: a proposal for reporting. Meta-analysis of
observational studies in epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
35 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews
and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
36 Araki E, Kawamori R, Inagaki N, Watada H, Hayashi N, Horie Y, et al. Long-term safety
of linagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Obes
Metab 2013;15:364-71.
37 Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, et al. Linagliptin
monotherapy in type 2 diabetes patients for whommetformin is inappropriate: an 18-week
randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled
extension. Diabetes Obes Metab 2012;14:1145-54.
38 Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, et al. Efficacy and
safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to
metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet
2010;376:431-9.
39 Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM, et al. One-year
treatment with exenatide improves (beta)-cell function, compared with insulin glargine, in
metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care
2009;32:762-8.
40 Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, et al. Use of
twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized,
controlled trial. Ann Intern Med 2011;154:103-12.
41 Chacra AR, Tan GH, Ravichandran S, List J, Chen R; CV181040 Investigators. Safety
and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated
sulphonylurea over 76 weeks. Diab Vasc Dis Res 2011;8:150-9.
42 Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, et al. Once weekly
exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes
(DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43.
43 Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE. Efficacy and
safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized,
double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).
Diabetes Care 2012;35:1225-31.
44 Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, et al. 2-year
efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes
inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Lancet 2012;380:475-83.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g2366 doi: 10.1136/bmj.g2366 (Published 14 April 2014) Page 7 of 19
RESEARCH
 o
n
 19 M
arch 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.g2366 on 15 April 2014. Downloaded from 
45 Gallwitz B, Guzman J, Dotta F, Guerci B, Simo R, Basson BR, et al. Exenatide twice daily
versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes
with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet
2012;379:2270-8.
46 Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez
I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono):
a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet
2009;373:473-81.
47 Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy
with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2
diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind,
placebo-controlled study. Diabet Med 2012;29:1260-7.
48 Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination
of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized,
double-blind, placebo-controlled study. Diabetes Obes Metab 2012;14:565-74.
49 Henry RR, Mudaliar S, Kanitra L, Woloschak M, Balena R; T-Emerge 3 Study Group.
Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled
with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial. J Clin Endocrinol Metab
2012;97:2370-9.
50 Hollander PL, Li J, Frederich R, Allen E, Chen R; CV181013 Investigators. Safety and
efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2
diabetes mellitus. Diab Vasc Dis Res 2011;8:125-35.
51 Hollander P, Lasko B, Barnett AH, Bengus M, Kanitra L, Pi-Sunyer FX, et al. Effects of
taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes
(T-emerge 7 study). Obesity (Silver Spring) 2013;21:238-47.
52 Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T. Efficacy and safety profile of exenatide
once weekly compared with insulin once daily in Japanese patients with type 2 diabetes
treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label,
parallel-group, multicenter, noninferiority study. Clin Ther 2012;34:1892-908 e1.
53 Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RG. Exenatide
exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients
with suboptimally controlled type 2 diabetes. Endocr J 2009;56:415-24.
54 Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved glycaemic control with minimal
hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1
analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.
Diabetes Obes Metab 2010;12:341-7.
55 Kikuchi M, Haneda M, Koya D, Tobe K, Onishi Y, Couturier A, et al. Efficacy and tolerability
of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes
mellitus. Diabetes Res Clin Pract 2010;89:216-23.
56 Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy
of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment.
Diabetes Obes Metab 2012;14:1032-9.
57 Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide,
a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces
greater improvements in glycaemic and weight control compared with adding rosiglitazone
or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
58 Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Treatment with the
human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with
metformin improves glycemic control and lowers body weight in patients with type 2
diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled
study. Diabetes Care 2009;32:1237-43.
59 Nauck M, Horton E, Andjelkovic M, Ampudia-Blasco FJ, Parusel CT, Boldrin M, et al.
Taspoglutide, a once-weekly glucagon-like peptide1 analogue, vs. insulin glargine titrated
to target in patients with type 2 diabetes: an open-label randomized trial. Diabet Med
2013;30:109-13.
60 Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, et al. Long-term efficacy
and safety comparison of liraglutide, glimepiride and placebo, all in combination with
metformin in type 2 diabetes: 2-year results from the LEAD-2 study.Diabetes Obes Metab
2013;15:204-12.
61 Amylin Pharmaceuticals, LLC. Effect of AC2993 compared wiith insulin glargine in patients
with type 2 diabetes also using combination therapy with sulfonylurea and metformin.
National Library of Medicine (US), 2000. http://clinicaltrials.gov/show/NCT00082381.
62 Merck. An investigational drug study in patients with type 2 diabetes mellitus. National
Library of Medicine (US), 2000. http://clinicaltrials.gov/show/NCT00094770.
63 Merck. MK0431 (sitagliptin) and metformin co-administration factorial study in patients
with type 2 diabetes mellitus. National Library of Medicine (US), 2000. http://clinicaltrials.
gov/show/NCT00103857.
64 Bristol-Myers Squibb. A phase 3 study of BMS-477118 in combination with metformin in
subjects with type 2 diabetes who are not controlled with diet and exercise. National
Library of Medicine (US), 2000. http://clinicaltrials.gov/show/NCT00327015.
65 Boehringer Ingelheim Pharmaceuticals. Efficacy and safety of 3 doses of BI1356
(linagliptin) in type 2 diabetes patients. National Library of Medicine (US), 2000. http://
clinicaltrials.gov/show/NCT00328172.
66 Takeda. Efficacy of alogliptin with pioglitazone (Actos®) in subjects with type 2 diabetes
mellitus. National Library of Medicine (US), 2000. http://clinicaltrials.gov/show/
NCT00395512.
67 Merck. MK0431A comparative study in patients with type 2 diabetes. National Library of
Medicine (US), 2000. http://clinicaltrials.gov/show/NCT00482729.
68 AstraZeneca; Bristol-Myers Squibb. 52-week add-on tometformin comparison of saxagliptin
and sulphonylurea, with a 52-week extension period. National Library of Medicine (US),
2000. http://clinicaltrials.gov/show/NCT00575588.
69 AstraZeneca; Bristol-Myers Squibb. Treatment effect of saxagliptin compared with placebo
in patients with type 2 diabetes and renal impairment. National Library of Medicine (US),
2000. http://clinicaltrials.gov/show/NCT00614939.
70 Merck. MK0431 and pioglitazone co-administration factorial study in patients with type 2
diabetes mellitus (0431-102 AM2). National Library of Medicine (US), 2000. http://
clinicaltrials.gov/show/NCT00722371.
71 Bristol-Myers Squibb. Safety and efficacy of saxagliptin plus insulin with or without
metformin. National Library of Medicine (US), 2000. http://clinicaltrials.gov/show/
NCT00757588.
72 Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company. Efficacy and safety of
linagliptin in combination with insulin in patients with type 2 diabetes. National Library of
Medicine (US), 2000. http://clinicaltrials.gov/show/NCT00954447.
73 JanssenResearch andDevelopment, LLC. TheCANTATA-D2 trial (CANagliflozin treatment
and trial analysis—DPP-4 Inhibitor Second Comparator Trial). National Library of Medicine
(US), 2000. http://clinicaltrials.gov/show/NCT01137812.
74 Boehringer Ingelheim Pharmaceuticals. Comprehensive add on study in Japan. National
Library of Medicine (US), 2000. http://clinicaltrials.gov/show/NCT01204294.
75 Takeda. Efficacy and safety of alogliptin in participants with type 2 diabetes. National
Library of Medicine (US), 2000. http://clinicaltrials.gov/show/NCT01289119.
76 Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J. Efficacy and safety of saxagliptin in
drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial.
Diabetes Metab Res Rev 2012;28:268-75.
77 Pratley RE, Urosevic D, Boldrin M, Balena R. Efficacy and tolerability of taspoglutide
versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or
sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).Diabetes
Obes Metab 2013;15:234-40.
78 Ratner RE, Rosenstock J, Boka G; DR16012 Investigators. Dose-dependent effects of
the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes
inadequately controlled with metformin: a randomized, double-blind, placebo-controlled
trial. Diabet Med 2010;27:1024-32.
79 Raz I, Hoekstra J, Fonseca V, Boldrin M, Kipnes M, Balena R, et al. Efficacy and safety
of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of
treatment: results of a randomized, double-blind, placebo-controlled phase 3 study
(T-emerge 1). Diabetes Care 2012;35:485-7.
80 Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting
GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly,
biweekly, and monthly dosing. Diabetes Care 2009;32:1880-6.
81 Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to
insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight
gain or increased hypoglycaemia. Diabetes Obes Metab 2009;11:1145-52.
82 Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ. Efficacy and
safety of linagliptin 2.5mg twice daily versus 5mg once daily in patients with type 2 diabetes
inadequately controlled on metformin: a randomised, double-blind, placebo-controlled
trial. Curr Med Res Opin 2012;28:1465-74.
83 Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin
glargine and placebo in combination with metformin and sulfonylurea therapy in type 2
diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia
2009;52:2046-55.
84 Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, Gonzalez JG, ChanM, et al. Efficacy
and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used
as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week
double-blind study. Diabetes Care 2012;35:252-8.
85 Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human
GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with
type 2 diabetes. Curr Med Res Opin 2010;26:1013-22.
86 Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added
to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind,
placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes
Metab 2012;14:927-36.
87 Seino Y, Min KW, Niemoeller E, Takami A, Abe N, Arai K, et al. Randomized, double-blind,
placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian
patients with type 2 diabetes insufficiently controlled on basal insulin with or without a
sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012;14:910-7.
88 Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ. The effects
of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized,
placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes:
the EGO study. Diabetes Obes Metab 2011;13:418-25.
89 YangW, Chen L, Ji Q, Liu X, Ma J, Tandon N, et al. Liraglutide provides similar glycaemic
control as glimepiride (both in combination with metformin) and reduces body weight and
systolic blood pressure in Asian population with type 2 diabetes from China, South Korea
and India: a 16-week, randomized, double-blind, active control trial.Diabetes Obes Metab
2011;13:81-8.
90 Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety
of the human glucagon-like peptide-1 analog liraglutide in combination with metformin
and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care
2009;32:1224-30.
91 Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with
exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes
Care 2010;33:2349-54.
92 Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL. Exenatide therapy and
the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes
Technol Ther 2012;14:904-11.
93 Sudhakaran C, Kishore U, Anjana RM, Unnikrishnan R, Mohan V. Effectiveness of
sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care
center experience. Diabetes Technol Ther 2011;13:27-32.
94 Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide
1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes
mellitus: a population-based matched case-control study. JAMA Intern Med
2013;173:534-9.
95 Giorda CB, Picariello R, Nada E, Tartaglino B, Marafetti L, Costa G, et al. Incretin therapies
and risk of hospital admission for acute pancreatitis in an unselected population of
European patients with type 2 diabetes: a case-control study. Lancet Diabetes Endocrinol
2014;2:111-5.
96 Dore DD, Seeger JD, Chan KA. Use of a claims-based active drug safety surveillance
system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to
metformin or glyburide. Curr Med Res Opin 2009;25:1019-27.
97 Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, et al. A cohort
study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab
2011;13:559-66.
98 Wenten M, Gaebler JA, Hussein M, Pelletier EM, Smith DB, Girase P, et al. Relative risk
of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic
medication: a follow-up study. Diabet Med 2012;29:1412-8.
99 Halfdanarson TR, Pannala R. Incretins and risk of neoplasia. BMJ 2013;346:f3750.
100 Alves C, Batel-Marques F, Macedo AF. Ameta-analysis of serious adverse events reported
with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract
2012;98:271-84.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g2366 doi: 10.1136/bmj.g2366 (Published 14 April 2014) Page 8 of 19
RESEARCH
 o
n
 19 M
arch 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.g2366 on 15 April 2014. Downloaded from 
101 Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis
risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16:48-56.
102 SAFEGUARD. SAFEGUARD safety evaluation of adverse reactions in diabetes. www.
safeguard-diabetes.org/?q=content/home.
Accepted: 19 March 2014
Cite this as: BMJ 2014;348:g2366
This is an Open Access article distributed in accordance with the Creative Commons
Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute,
remix, adapt, build upon this work non-commercially, and license their derivative works
on different terms, provided the original work is properly cited and the use is
non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g2366 doi: 10.1136/bmj.g2366 (Published 14 April 2014) Page 9 of 19
RESEARCH
 o
n
 19 M
arch 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.g2366 on 15 April 2014. Downloaded from 
Tables
Table 1| Characteristics of randomised controlled trials of incretin treatment in patients with type 2 diabetes mellitus
Mean
diabetes
duration
(years)
Mean
FPG
(mmol/L)
Mean
HbA1c
(%)
Mean
BMI
Mean
age
(years)No (%) male
Follow
up
(weeks)
No of
groups
Total No
of
patients
Study
phase
No of
study
sites
No of
countries
involved
International
studyAuthor (year)
286
(51.0)*
9.182560395 (70.4)124561III471NoAraki (2013)36
165
(75.0)*
10.18.129.556.588 (38.8)182227III537YesBarnett (2012)37
5.79.18.53252.3254 (51.7)263514III723YesBergenstal (2010)38
4.99.27.530.558.445 (65.2)52269III33YesBunck (2009) 39
128.18.433.559148 (57.1)302261III595YesBuse (2011)40
6.99.68.42955.1346 (45.1)763768IIINRNRYesChacra (2011)41
7.99.88.33258243 (53.3)262467III7216YesDiamant (2010)42
1.3‡9831.953.7186 (51.5)122361III6112YesFonseca (2012) 43
715
(47.1)*
9.17.730.256.6933 (60.2)10421551III20916YesGallwitz (2012)a44
5.78.87.532.556524 (53.6)234†21029III12814YesGallwitz (2012)b45
5.49.48.333.153371 (49.7)523746III1382YesGarber (2009)46
3.9NR7.332.156.674 (45.1)125164II447YesGrunberger (2012)
47
562
(74.3)*
10.98.729.155.3426 (53.9)246791III13314YesHaak (2012) 48
7.79.48.132.654.1170 (54.3)243326III1138YesHenry (2012) 49
5.29.08.33054280 (49.6)763565III1338YesHollander (2011) 50
5.18.97.536.753.5119 (40.8)242305III638YesHollander (2012) 51
9NR8.526.156.8290 (67.9)262427IIINR1NoInagaki (2012) 52
11.99.2825.360.3104 (68.9)124153II201NoKadowaki (2009) 53
10.39.58.424.959.7169 (64)243264NR491NoKaku (2010) 54
9.29.17.924.559.7144 (71.3)122202III291NoKikuchi (2010) 55
16.68.87.830.366.5207 (56.1)522369NR10813YesKothny (2012) 56
6.6‡9.88.429.956.1516 (49.6)2651041III11621YesMarre (2009) 57
5.3NR7.932.755.7143 (48.1)126306IINR49YesNauck (2009) 58
9.311.18.332.457.7549 (53.4)2431049III18725YesNauck (2013) a59
7.6108.43156.7635 (58.2)10451091III17021YesNauck (2013)b60
9.610.28.231.458.9306 (55.7)262551III8213YesNCT00082381
(2009) 61
6.49.27.731.256.7694 (59.2)10421172III173NRYesNCT00094770
(2009) 62
NR11.18.8NR53.5539 (49.4)1045915III140NRYesNCT00103857
(2009) 63
1.711.19.530.252643 (49.2)2441306III21113YesNCT00327015
(2009) 64
NR10.58.331.157.3175 (57.9)125302II716YesNCT00328172
(2011) 65
3.210.68.831.152.6320 (48.9)264655III26823YesNCT00395512
(2013) 66
NRNR9.9NR49.7708 (56.8)4421250III2292YesNCT00482729
(2009) 67
5.497.731.457.5444 (51.7)1042858III13011YesNCT00575588
(2010)68
16.79.98.330.766.573 (42.9)522170III7514YesNCT00614939
(2011) 69
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Table 1 (continued)
Mean
diabetes
duration
(years)
Mean
FPG
(mmol/L)
Mean
HbA1c
(%)
Mean
BMI
Mean
age
(years)No (%) male
Follow
up
(weeks)
No of
groups
Total No
of
patients
Study
phase
No of
study
sites
No of
countries
involved
International
studyAuthor (year)
NRNRNRNRNR912 (56.5)5471615IIINRNRNRNCT00722371
(2011) 70
11.99.68.732.357.2188 (41.3)522455III7210YesNCT00757588
(2011) 71
NR8.38.33160658 (52.2)5221261III16719YesNCT00954447
(2012) 72
NRNRNRNR56.5422 (55.9)522755III14017YesNCT01137812
(2013) 73
NRNR8NR61.3246 (69.9)524352III431NoNCT01204294
(2012) 74
4.1NRNR25.752.6275 (54.3)166506III301NoNCT01289119
(2013) 75
19.18.225.951.4315 (55.5)242568III404YesPan (2012) 76
8.8108.332.756.4362 (48.9)243760III13017YesPratley (2013) 77
6.68.87.531.956.2270 (49.8)139542NR1337YesRatner (2010) 78
2.48.87.632.354.8130 (36.7)243373III53NRYesRaz (2012) 79
4.99.8832.153.5170 (47.8)1610361II1184YesRosenstock (2009)
a80
12.610.69.332.555.4161 (41.3)263390III11013YesRosenstock (2009)
b81
227
(47.5)*
9.2829.658.6280 (57.0)123491II819YesRoss (2012) 82
9.4NR8.330.557.5326 (56.6)263581III10717YesRussell-Jones
(2009)83
2.7NR8.531.253.8484 (59.0)264820III12422YesRussell-Jones
(2012) 84
8.211.38.924.558.3268 (67)242411III751NoSeino (2010) 85
6.3NR825.952.6198 (68.8)123288III301NoSeino (2012)a 86
13.97.78.525.358.4149 (47.9)242311III574YesSeino (2012)b 87
8.3NR8.233.956.5129 (36.4)162262II392YesUmpierrez (2011) 88
7.59.78.625.653.3514 (55.3)164929NR513YesYang (2011) 89
910.18.533.555302 (56.7)263533III962YesZinman (2009) 90
BMI=body mass index; FPG=fasting plasma glucose; NR=not reported.
*No (%) of patients with no more than 5 years’ diabetes duration.
†Longest follow-up time (weeks).
‡Median duration of diabetes (years).
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Table 2| Intervention characteristics of randomised controlled trials of incretin treatment in patients with type 2 diabetes mellitus
Follow-up from start
of treatment
(weeks)
ControlIncretin
Drugs used across groupsAuthor (year) EventsTypeEventsType
120/80Placebo0/319LinagliptinNoneAraki (2013)36
0/162Voglibose0/319Linagliptin
180/76Placebo0/151LinagliptinNoneBarnett (2012)37
262/165Pioglitazone0/160ExenatideMetforminBergenstal (2010)38
2/165Pioglitazone0/166Sitagliptin
520/33Insulin glargine1/36ExenatideMetforminBunck (2009)39
300/122Placebo0/137ExenatideInsulin glargine ± metformin/pioglitazone (or
both agents)
Buse (2011)40
760/267Placebo0/501SaxagliptinGlyburideChacra (2011)41
260/223Insulin glargine1/233ExenatideMetformin ± SUDiamant (2010)42
120/122Placebo0/239LixisenatideNoneFonseca (2012)43
1040/775Glimepiride1/776LinagliptinMetforminGallwitz (2012)a44
107*1/508Glimepiride1/511ExenatideMetforminGallwitz (2012)b45
520/248Glimepiride2/497LiraglutideNoneGarber (2009)46
121/32Placebo0/132DulaglutideNoneGrunberger (2012)47
240/72Placebo0/428LinagliptinNoneHaak (2012)48
240/101Placebo0/223TaspoglutideMetforminHenry (2012)49
760/184Placebo1/381SaxagliptinTZDHollander (2011)50
240/150Placebo0/154TaspoglutideMetforminHollander (2012)51
260/212Insulin glargine0/215ExenatideBG or BG + TZDInagaki (2012) 52
120/40Placebo0/111ExenatideSU ± BG/TZDKadowaki (2009) 53
240/88Placebo0/176liraglutideSU (glibenclamide, glicazide or glimeprimide)Kaku (2010) 54
120/100Placebo0/102VildagliptinGlimepirideKikuchi (2010)55
520/153Placebo0/216VildagliptinUntreated, insulin, OADs or any combinationKothny (2012) 56
260/114Placebo1/695LiraglutideGlimepirideMarre (2009)57
0/231Rosiglitazone1/695Liraglutide
120/49Placebo0/248TaspoglutideMetforminNauck (2009)58
240/322Insulin glargine0/715TaspoglutideMetforminNauck (2013)a 59
1040/121Placebo1/724LiraglutideMetforminNauck (2013) b60
1/242Glimepiride1/724Liraglutide
261/267Insulin glargine0/282ExenatideMetformin + SUNCT00082381 (2009)61
1040/584Glipizide1/588SitagliptinMetforminNCT00094770 (2009) 62
1040/364Metformin1/551SitagliptinNoneNCT00103857 (2009) 63
241/328Metformin0/978SaxagliptinNoneNCT00327015 (2009)64
120/67Placebo1/170LinagliptinNoneNCT00328172 (2011) 65
0/65Metformin1/170Linagliptin
260/163Pioglitazone1/491AlogliptinNoneNCT00395512 (2013) 66
440/621No additional drug1/625SitagliptinMetforminNCT00482729 (2009)67
1041/430Glipizide0/428SaxagliptinMetforminNCT00575588 (2010) 68
521/85Placebo0/85SaxagliptinOADs and/or insulinNCT00614939 (2011) 69
541/693Pioglitazone0/922SitagliptinNoneNCT00722371 (2011) 70
520/151Placebo0/304SaxagliptinInsulin ± metforminNCT00757588 (2011) 71
521/630Placebo3†/631LinagliptinInsulin and/or metformin and/or pioglitazoneNCT00954447 (2012) 72
521/377Canagliflozin0/378SitagliptinMetformin + SUNCT01137812 (2013) 73
520/124Metformin0/228LinagliptinSU or A-GINCT01204294 (2012)74
161/92Placebo0/252AlogliptinNoneNCT01289119 (2013) 75
0/98Metformin0/252Alogliptin
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Table 2 (continued)
Follow-up from start
of treatment
(weeks)
ControlIncretin
Drugs used across groupsAuthor (year) EventsTypeEventsType
0/63Pioglitazone0/252Alogliptin
240/284Placebo0/284SaxagliptinNonePan (2012) 76
240/257Pioglitazone1/494TaspoglutideSU ± metforminPratley (2013) 77
130/109Placebo0/433LixisenatideMetforminRatner (2010) 78
240/123Placebo0/245TaspoglutideNoneRaz (2012) 79
160/51Placebo0/35ExenatideNoneRosenstock (2009) a80
0/51Placebo0/270Albiglutide
260/129Placebo2/260AlogliptinInsulin ± metforminRosenstock (2009)b81
120/44Placebo0/447LinagliptinmetforminRoss (2012) 82
0/114Placebo0/230LiraglutideMetformin + glimepirideRussell-Jones (2009) 83
260/232Insulin glargine0/230Liraglutide
260/246Metformin0/248ExenatideNoneRussell-Jones (2012) 84
0/163Pioglitazone0/248Exenatide
0/246Metformin1/163Sitagliptin
0/163Pioglitazone1/163Sitagliptin
240/132Glibenclamide0/268LiraglutideNoneSeino (2010) 85
120/100Placebo0/188AlogliptinMetforminSeino (2012)a 86
240/157Placebo0/154LixisenatideInsulin ± SUSeino (2012)b 87
160/66Placebo2/196DulaglutideEach of the two different classes (SU,
biguanide, TZD or DPP-4)
Umpierrez (2011)88
160/231Glimepiride0/697LiraglutideMetforminYang (2011)89
260/177Placebo0/356LiraglutideMetformin + rosiglitazoneZinman (2009) 90
SU=sulfonylurea; TZD=thiazolidinedione; BG=biguanide; OADs=oral antidiabetic drugs.
*Average treatment time (weeks); A-GI, alpha-glucosidase inhibitor.
†Pancreatitis events data extracted from additional information reported in ClinicalTrials.gov.
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Table 3| Characteristics of observational studies of incretin treatment and pancreatitis in patients with type 2 diabetes mellitus
Mean
diabetesMean
FPG
(mmol/L)
Mean
HbA1c
(%)
Mean
BMI
Mean
age
(years)
No (%)
maleExclusion criteriaInclusion criteriaFunding
Data
source/countryStudy design
Author
(year)
duration
(years)
NRNRNRNR52.726953
(54.3)
Patients aged >63
because of
possibility of
incomplete medical
data; patients with
acute pancreatitis 6
Diabetic patients aged
18-63 years with pharmacy
and medical claims data
for continuous period of at
least 12 months between
1 January 2007 and 30
June 2009
NRClaims data/USRetrospective
cohort study
Garg
(2010)91
months before or on
index date; treatment
with repaglinide,
nateglinide,
acarbose, or miglitol
and treatment with
both exenatide and
sitagliptin
3.1NRNRNR63.1145560
(54.2)
Users of sitagliptin
were patients aged
<18; patients with
pancreatic cancer
subsequent to
incident cancer
Patients having two or
more medical claims with
ICD-9 code of 250.xx
within calendar year and
fewer than two claims with
ICD-9 code of 250.x1
Public
funding
Claims data/USRetrospective
cohort study
Romley
(2012)92
diagnosis; patientswithin each year, using
with occurrence oforal antidiabetes drugs at
first event beforeany point during study
2007 or before first
use of exenatide
period, and enrolled for at
least 1 year during
2007-09 with continuously
enrolled throughout each
year, with no gaps
between years
15.110.09.230.055.13512
(63.2)
NRAsian Indian patients with
type 2 diabetes in Indian
tertiary diabetes care
centre
No
financial
support
Case
records/India
Retrospective
cohort study
Sudhakaran
(2011) 93
NRNRNRNR521458
(57.5)
Participants aged
>64 because of
incomplete
healthcare
information;
pancreatitis
Type 2 diabetes mellitus
patients who filled at least
1 prescription for any drug
used to treat type 2
diabetes from 1 February
2005 to 31 December
Public
funding
Claims data/USCase-control
study
Singh
(2013)94
occurrences within 3
months of enrollment
2008; patients aged 18-64
on date of first code for
diabetes, and contributed
at least 6 months of
medical or pharmacy
coverage in calendar year
with diabetes code, and of
known sex
NRNRNRNR72.22750
(54.8)
Individuals who had
ICD-9-CM code for
type 1 diabetes
mellitus (250.x1 or
250.x3)
Type 2 diabetes patients
aged ≥41 who were
dispensed at least one
dose of any drug to treat
diabetes between 1 Jan
2008 and 31 Dec 2012
Non-profit
funding
Claims data/ItalyCase-control
study
Giorda
(2013) 95
NR=not reported.
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Table 4| Exposures, outcomes, and results of observational studies of incretin treatment and pancreatitis in patients with type 2 diabetes
mellitus
Adjusted estimates (95% CI)
Total No of
patients
No of
eventsOutcome measuresControl groupExposure of interestAuthor (year)
Exenatide v control: HR 0.9 (0.6 to 1.5);
sitagliptin v control: HR 1.0 (0.7 to 1.3)
38 615154Acute pancreatitisDiabetic control group
(new sulfonylurea,
biguanide, or
thiazolidinedione and no
sitagliptin or exenatide
prescription)
Exenatide, sitagliptinGarg (2010)91
Exenatide v control: OR 0.93 (0.63 to
1.36)
268 5611 312Admission for acute
pancreatitis
Non-exenatideExenatideRomley (2012) 92
No events reported5 5600Acute pancreatitisInsulin glargineSitagliptinSudhakaran
(2011) 93
Current use of sitagliptin or exenatide
within 30 days before pancreatitis v no
use: OR 2.24 (1.36 to 3.68); recent use
past 30 days and <2 years v no use:
OR 2.01 (1.37 to 3.18); any use within
2 years v no use: OR 2.07 (1.36 to
3.13)
2 5381 269Admission for acute
pancreatitis
No sitagliptin or exenatide
prescription
Exenatide, sitagliptinSingh (2013) 94
All incretin agents v control: OR 0.98
(0.69 to 1.38)
5 0151 003Admission for acute
pancreatitis
Not clearly reportedExenatide, liraglutide,
sitagliptin, saxagliptin,
vildagliptin
Giorda (2013)95
HR=hazard ratio; OR=odds ratio.
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Table 5| Risk of bias of cohort studies of incretin treatment and pancreatitis in patients with type 2 diabetes mellitus
Completeness
of outcome and
Assessment
of outcome
Comparability of study
controls for important
factors
Demonstration
that outcome of
interest not
Ascertainment
of other
confounding
variables
Selection of
non exposed
cohort
Ascertainment
of exposure to
incretin agents
Ascertainment of
type 2 diabetes
conditions
Author
(year)
exposure
variables
present at start
of study
Completeness of
outcome and
exposure
variable data in
database not
mentioned
Acute
pancreatitis
determined
by claim for
ICD-9 code
577.0
Cox proportional hazard
model built to control for
age, sex,
hypertriglyceridaemia,
alcohol abuse, biliary
stone disease,
Yes, patients with
acute pancreatitis
6 months before
or on index date
were excluded
Risk factors for
acute
pancreatitis
determined from
ICD-9 claims
data
Drawn from
same
population as
exposed
cohort
Statement not
explicit; likely
from new
antidiabetes
drug of
pharmacy
claims
Patients with
diabetes identified by
presence of at least
1 ICD-9 code of
250.XX and claim for
new antidiabetes
drugs
Garg (2010)
91
cholestatic liver disease,
and drug therapy
Completeness of
outcome and
exposure
variable data in
database not
mentioned
Admission for
pancreatitis
identified by
inpatient
claims with
ICD-9 code
577.0
Logistic analyses used
to control for influence of
age, sex, years since
diabetes diagnosis, 19
co-morbid conditions,
and traditional risk
factors for pancreatitis
Yes, patients
excluded if
pancreatitis
occurred before
enrolment and
use of exenatide
Co-morbid
conditions and
traditional
pancreatitis risk
factors, such as
history of
gallstones or
Drawn from
same
population as
exposed
cohort
Exenatide use
identified by
National Drug
Code within
pharmacy
claims
Patients with type 2
diabetes identified
with ICD code
(250.XX and 250.X1)
and with use of
antidiabetes drugs
identified by National
Romley
(2012) 92
(such as gallstones or
alcohol abuse)
alcohol abuse,
identified from
ICD-9 codes
Drug Code within
pharmacy claims
All patients with
complete follow
up
Medical
records
No, patients had
significant difference in
age, sex, BMI, duration
of diabetes between
sitagliptin and insulin
glargine, and no
Not reportedNot reportedDrawn from
same
population as
exposed
cohort
Statement not
explicit; likely
from medical
records
Patients with type 2
diabetes prescribed
sitagliptin or insulin
glargine identified
frommedical records
Sudhakaran
(2011)93
adjusted analysis
conducted
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Table 6| Risk of bias in case-control studies of incretin treatment and pancreatitis in patients with type 2 diabetes mellitus
Completeness
of data within
database
Comparability
of study
controls for
Same method
of
ascertainmentAscertainment of
other confounding
variables
Ascertainment
of exposure to
incretin agents
Definition
of controls
Selection of
controls
Is case
definition
adequate
Ascertainment
of type 2
diabetes
conditions
Author
(year)
important
factors
for exposure to
incretin agents
Both groups
had same rate
of missing
information on
sex
Logistic
regression
model used
control for
matching
variables,
Yes, both
groups used
drug use
information from
computerised
pharmacy
Ascertainment of risk
factors for acute
pancreatitis not
mentioned
Drug exposure
defined as
having filled
prescription for
sitagliptin or
exenatide
Patients
with no
acute
pancreatitis
Each case
randomly
selected 1
control subject
from
same
population
Yes,
presumptive
cases
identified
with
validated
algorithm of
ICD-9 and
Type 2 diabetes
mellitus
identified as 1
relevant
inpatient code
of ICD-9 or 2
outpatient ICD-9
codes
separated by at
Singh
(2013)94
potential
confounders
specified a priori
database
containing date
of prescription
before first
observed
diagnosis of
matched on
age within 10Current
least 30 days and identifiablefilled andpancreatitis, andyears, sex,Procedural
(250.xx, 648.0, in claims data,supplied toprescription datainsurance planTerminology
362.0, and
266.41)
and metformin
exposure during
same period
determine
exposure to
sitagliptin or
used as
indicator of drug
exposure
site, diabetes
complication
severity index
codes for
acute
pancreatitis
exenatide, and(0, 1, 2, 3, or
patient withmore), and
exposure afterenrolment
index diagnosispattern or
of acuteduration of
follow-up pancreatitis
counted as
unexposed
Authors did not
mention
completeness
of outcome and
exposure
variable data in
database
Logistic
regression
model built to
control for
confounders,
including past
history of
Yes, both cases
and controls
who had been
prescribed
incretins
identified with
regional drug
database
Potential confounders
identified from ICD-9
codes, such as chronic
or acute pancreatitis
(excluding episode of
index case (ICD-9
code 577.0)),
gallstones, alcohol
Incretins
selected by
anatomical
therapeutic
chemical (ATC)
classification
system (ATC
codes A10BH01
Patients
with no
acute
pancreatitis
Each case
randomly
selected four
controls from
same
population
source,
matched for
Yes, cases
identified by
having at
least one
discharge for
acute
pancreatitis
(ICD-9 code
Patients with
type 2 diabetes
identified as at
least 1 dose of
any drug to treat
diabetes and
patients with
type 1 diabetes
Giorda
(2013)95
pancreatitis,
misuse,and A10BD07year of birth,577.0excluded by gallstones,
hypertriglyceridaemia,(sitagliptin),sex, and yeardischargeICD-9 code ( alcohol use,
obesity, biliary tract orA10BH02 andof firstdiagnosis at250.x1 or
250.x3)
hypertrigly
ceridaemia,pancreatic cancers,A10BD08exposure toany time
obesity, biliarycardio vascular(vildagliptin),antidiabetic
drugs
after first
exposure to tract ordiseases, and diabetic
retinopathy
A10BH03
(saxagliptin),antidiabetic
drugs)
pancreatic
cancer,A10BX04
cardiovascular(exenatide), and
disease, andA10BX07
(liraglutide)) metformin or
glibenclamide
use
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Figures
Fig 1 Flow chart of article selection. *Data from ClinicalTrials.gov
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Fig 2 Risk of pancreatitis events between patients with type 2 diabetes mellitus treated with incretin or control
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